<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ASTRAMORPH- morphine sulfate injection </strong><br> AstraZeneca LP<br></p></div>
<h1> ASTRAMORPH/PF™<br><span class="Italics">(morphine sulfate injection, USP</span>) Preservative-Free CS-ll</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1> DESCRIPTION</h1>
<p class="First"> Morphine is the most important alkaloid of opium and is a phenanthrene  derivative.  It is available as the sulfate salt, having the following  structural formula:</p>
<p> 7,8-Didehydro-4,5-epoxy-17-methyl-(5α,6α)-morphinan-3,6-diol  sulfate (2:1) (salt), pentahydrate</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=CA44184D-4D3B-4FDA-C288-8C32527EA6CA&amp;name=astramorph-chemstructure.jpg"></div>
<p> (C<span class="Sub">17</span> H<span class="Sub">19</span> NO<span class="Sub">3</span> )<span class="Sub">2</span> •H<span class="Sub">2</span> SO<span class="Sub">4</span> •5H<span class="Sub">2</span> OMolecular Weight is 758.83</p>
<p> Preservative-free ASTRAMORPH/PF (Morphine Sulfate Injection, USP) is a  sterile, nonpyrogenic isobaric solution of morphine sulfate free of  antioxidants, preservatives or other potentially neurotoxic additives,  and is intended for intravenous, epidural or intrathecal administration  as a narcotic analgesic.  Each milliliter contains morphine sulfate 0.5  mg or 1 mg and sodium chloride 9 mg in Water for Injection.  pH range  is 2.5-6.5.  Ampules and vials are sealed under nitrogen.  Each ampule  and vial is intended for <span class="Bold">SINGLE USE ONLY</span> .  <span class="Italics">Discard any unused portion</span> .  DO NOT HEAT-STERILIZE.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1> CLINICAL PHARMACOLOGY</h1>
<p class="First"> Morphine produces a wide spectrum of pharmacologic effects including  <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>,  diminished gastrointestinal motility and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Opiate  <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> involves at least three anatomical areas of the central  nervous system: the periaqueductal-periventricular gray matter, the  ventromedial medulla and the spinal cord. A systemically administered  opiate may produce <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> by acting at any, all or some combination  of these distinct regions. Morphine interacts predominantly with the  µ-receptor. The µ-binding sites of opioids are very  discretely distributed in the human brain, with high densities of sites  found in the posterior amygdala, hypothalamus, thalamus, nucleus  caudatus, putamen and certain cortical areas. They are also found on  the terminal axons of primary afferents within laminae I and II  (substantia gelatinosa) of the spinal cord and in the spinal nucleus of  the trigeminal nerve. </p>
<p> Morphine has an apparent volume of distribution ranging from 1.0 to 4.7  L/kg after <span class="Italics">intravenous</span>  dosage. Protein binding is low, about 36%, and muscle tissue binding  is reported as 54%. A blood-brain barrier exists, and when morphine is  introduced outside of the CNS (eg. <span class="Italics">intravenously</span> ), plasma concentrations of morphine remain higher than the  corresponding CSF morphine levels. Conversely, when morphine is  injected into the <span class="Italics">intrathecal </span> space, it diffuses out into the systemic circulation slowly, accounting  for the long duration of action of morphine administered by this route.  </p>
<p> Morphine has a total plasma clearance which ranges from 0.9 to 1.2  L/kg/h (liters/kilogram/hour) in postoperative patients, but shows  considerable interindividual variation. The major pathway of clearance  is hepatic glucuronidation to morphine-3-glucuronide, which is  pharmacologically inactive. The major excretion path of the conjugate  is through the kidneys, with about 10% in the feces. Morphine is also  eliminated by the kidneys, 2 to 12% being excreted unchanged in the  urine. Terminal half-life is commonly reported to vary from 1.5 to 4.5  hours, although the longer half-lives were obtained when morphine  levels were monitored over protracted periods with very sensitive  radioimmunoassay methods. The accepted elimination half-life in normal  subject is 1.5 to 2 hours. </p>
<p> "Selective" blockade of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> sensation is possible by neuraxial  application of morphine. In addition, duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> may be much  longer by this route compared to systemic administration. However, CNS  effects, associated with systemic administration, are still seen. These  include <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, sedation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>  and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. In particular, both early and late respiratory  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (up to 24 hours post dosing) have been reported following  neuraxial administration. Circulation of the spinal fluid may also  result in high concentrations of morphine reaching the brain stem  directly. </p>
<p> The incidence of unwanted CNS effects, including delayed respiratory  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, associated with neuraxial application of morphine, is  related to the circulatory dynamics of the epidural venous plexus and  the spinal fluid. The lipid solubility and degree of ionization of  morphine plays an important part in both the onset and duration of  <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and the CNS effects. Morphine has a pK<span class="Sub">a </span> 7.9, with an octanol/water partition coefficient of 1.42 at pH 7.4. At  this pH, the tertiary amino group in each of the opioids is mostly  ionized, making the molecule water soluble. Morphine, with additional  hydroxyl groups on the molecule, is significantly more water-soluble  than any other opioid in clinical use. </p>
<p> Morphine, injected into the <span class="Italics">epidural space</span> , is rapidly absorbed into the general circulation. Absorption is so  rapid that the plasma concentration-time profiles closely resemble  those obtained after intravenous or intramuscular administration. Peak  plasma concentrations averaging 33-40 ng/mL (range 5-62 ng/mL) are  achieved within 10 to 15 minutes after administration of 3 mg of  morphine. Plasma concentrations decline in a multiexponential fashion.  The terminal half-life is reported to range from 39 to 249 minutes  (mean of 90 ± 34.3 min) and, though somewhat shorter, is similar in  magnitude as values reported after intravenous and intramuscular  administration (1.5-4.5 h). CSF concentrations of morphine, after  epidural doses of 2 to 6 mg in postoperative patients, have been  reported to be 50 to 250 times higher than corresponding plasma  concentrations. The CSF levels of morphine exceed those in plasma after  only 15 minutes and are detectable for as long as 20 hours after the  injection of 2 mg of epidural morphine. Approximately 4% of the dose  injected epidurally reaches the CSF. This corresponds to the relative  minimum effective epidural and intrathecal doses of 5 mg and 0.25 mg,  respectively. The disposition of morphine in the CSF follows a biphasic  pattern, with an early half-life of 1.5 h and a late phase half-life of  about 6 h. Morphine crosses the dura slowly, with an absorption  half-life across the dura averaging 22 minutes. Maximum CSF  concentrations are seen 60-90 minutes after injection. Minimum  effective CSF concentrations for postoperative <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> average 150  ng/mL (range &lt;1-380 ng/mL). </p>
<p> The <span class="Italics">intrathecal route</span>  of administration circumvents meningeal diffusion barriers and,  therefore, lower doses of morphine produce comparable <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> to that  induced by the epidural route. After intrathecal bolus injection of  morphine, there is a rapid initial distribution phase lasting 15-30  minutes and a half-life in the CSF of 42-136 min (mean 90 ± 16 min).  Derived from limited data, it appears that the disposition of morphine  in the CSF, from 15 minutes postintrathecal administration to the end  of a six-hour observation period, represents a combination of the  distribution and elimination phases. Morphine concentrations in the CSF  averaged 332 ± 137 ng/mL at 6 hours, following a bolus dose of 0.3  mg of morphine. The apparent volume of distribution of morphine in the  intrathecal space is about 22 ± 8 mL. </p>
<p> Time-to-peak plasma concentrations, however, are similar (5-10 min)  after either epidural or intrathecal bolus administration of morphine.  Maximum plasma morphine concentrations after 0.3 mg intrathecal  morphine have been reported from &lt;1 to 7.8 ng/mL. The minimum  analgesic morphine plasma concentration during Patient-Controlled  <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> (PCA) has been reported as 20-40 ng/mL, suggesting that any  analgesic contribution from systemic redistribution would be minimal  after the first 30-60 minutes with epidural administration and  virtually absent with intrathecal administration of  morphine.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1> INDICATIONS AND USAGE:</h1>
<p class="First"> Astramorph/PF is a systemic narcotic analgesic for administration by  the intravenous, epidural or intrathecal routes.  It is used for the  management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> not responsive to non-narcotic analgesics.   Astramorph/PF, administered epidurally or intrathecally, provides <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>  relief for extended periods without attendant loss of motor, sensory or  sympathetic function.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1> CONTRAINDICATIONS:</h1>
<p class="First"> Astramorph/PF is contraindicated in those medical conditions which  would preclude the administration of opioids by the intravenous  route—<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to morphine or other opiates, acute bronchial  <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, upper airway obstruction.</p>
<p></p>
<p>Astramorph/PF, like all opioid analgesics, may cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in an individual whose ability to maintain blood pressure has already been compromised by a depleted blood volume or a concurrent administration of drugs, such as phenothiazines or general anesthetics. (See also, <span class="Bold">PRECAUTIONS: Use with Other Central Nervous System Depressants.)</span></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="robinsonja1130788196016"></a><a name="section-6"></a><p></p>
<h1> WARNINGS:</h1>
<p class="First"> Morphine sulfate may be habit forming. (See <a href="#robinsonja1130788114267"> DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a>.) <span class="Bold"></span>  <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> may cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p> Astramorph/PF administration should be limited to use by those familiar  with the management of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Rapid intravenous  administration may result in chest wall <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>.</p>
<p><span class="Bold">Prior to any epidural or intrathecal drug administration, the physician  should be familiar with patient conditions (such as <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at the  injection site, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis, anticoagulant therapy, etc.) which  call for special evaluation of the benefit versus risk potential.  </span></p>
<p> In the case of epidural or intrathecal administration, Astramorph/PF  should be administered by or under the direction of a physician  experienced in the techniques and familiar with the patient management  problems associated with epidural or intrathecal drug administration.  Because epidural administration has been associated with less potential  for immediate or late adverse effects than intrathecal administration,  the epidural route should be used whenever possible. SEVERE RESPIRATORY  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> UP TO 24 HOURS FOLLOWING EPIDURAL OR INTRATHECAL  ADMINISTRATION HAS BEEN REPORTED. </p>
<p><span class="Bold">BECAUSE OF THE RISK OF SEVERE ADVERSE EFFECTS WHEN THE EPIDURAL OR  INTRATHECAL ROUTE OF ADMINISTRATION IS EMPLOYED, PATIENTS MUST BE  OBSERVED IN A FULLY EQUIPPED AND STAFFED ENVIRONMENT FOR AT LEAST 24  HOURS AFTER THE INITIAL DOSE. </span></p>
<p></p>
<p> THE FACILITY MUST BE EQUIPPED TO RESUSCITATE PATIENTS WITH SEVERE  OPIATE OVERDOSAGE, AND THE PERSONNEL MUST BE FAMILIAR WITH THE USE AND  LIMITATIONS OF SPECIFIC NARCOTIC ANTAGONISTS (NALOXONE, NALTREXONE) IN  SUCH CASES. </p>
<div class="Section" data-sectionCode="">
<a name="section-6.1"></a><p></p>
<h2> Tolerance and Myoclonic Activity:</h2>
<p class="First"> PATIENTS SOMETIMES MANIFEST UNUSUAL ACCELERATION OF NEURAXIAL MORPHINE  REQUIREMENTS, WHICH MAY CAUSE CONCERN REGARDING SYSTEMIC ABSORPTION AND  THE HAZARDS OF LARGE DOSES; THESE PATIENTS MAY BENEFIT FROM  HOSPITALIZATION AND DETOXIFICATION. TWO CASES OF MYOCLONIC-LIKE SPASM  OF THE LOWER EXTREMITIES HAVE BEEN REPORTED IN PATIENTS RECEIVING MORE  THAN 20 MG/DAY OF INTRATHECAL MORPHINE. AFTER DETOXIFICATION, IT MIGHT  BE POSSIBLE TO RESUME TREATMENT AT LOWER DOSES, AND SOME PATIENTS HAVE  BEEN SUCCESSFULLY CHANGED FROM CONTINUOUS EPIDURAL MORPHINE TO  CONTINUOUS INTRATHECAL MORPHINE. REPEAT DETOXIFICATION MAY BE INDICATED  AT A LATER DATE. THE UPPER DAILY DOSAGE LIMIT FOR EACH PATIENT DURING  CONTINUING TREATMENT MUST BE INDIVIDUALIZED. </p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="robinsonja1130788473512"></a><a name="section-7"></a><p></p>
<h1> PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2> General:</h2>
<p class="First"> Control of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> by neuraxial opiate delivery is always accompanied by  considerable risk to the patients and requires a high level of skill to  be successfully accomplished. The task of treating these patients must  be undertaken by experienced clinical teams, well-versed in patient  selection, evolving technology and emerging standards of care. For  safety reasons, it is recommended that administration of Astramorph/PF  by the epidural or intrathecal routes be limited to the lumbar area.  Intrathecal use has been associated with a higher incidence of  <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> than epidural use. </p>
<p> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> may result from high doses. Patients with known <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>  disorders should be carefully observed for evidence of morphine-induced  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity. </p>
</div>
<div class="Section" data-sectionCode="">
<a name="section-7.2"></a><p></p>
<h2> Use in Patients with <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span> or Head  Injury:</h2>
<p class="First"> Astramorph/PF should be used with extreme caution in patients with head  injury or <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>. Pupillary changes (<span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>)  from morphine may obscure the existence, extent and course of  intracranial pathology. High doses of neuraxial morphine may produce  myoclonic events (see <a href="#robinsonja1130788196016"> WARNINGS</a>  and <a href="#robinsonja1130788222422"> ADVERSE REACTIONS</a> ). Clinicians should maintain a high index of suspicion for adverse  drug reactions when evaluating altered mental status or movement  abnormalities in patients receiving this modality of treatment.  </p>
</div>
<div class="Section" data-sectionCode="">
<a name="section-7.3"></a><p></p>
<h2> Use in Chronic Pulmonary Disease:</h2>
<p class="First"> Care is urged in using this drug in patients who have a decreased  respiratory reserve (eg., <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>, severe <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, kyphoscoliosis or  <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the phrenic nerve). Astramorph/PF should not be given in  cases of chronic <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, upper airway obstruction or in any other  chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">pulmonary disorder</span> without due consideration of the known risk  of <span class="product-label-link" type="condition" conceptid="319049" conceptname="Acute respiratory failure">acute respiratory failure</span> following morphine administration in such  patients. </p>
</div>
<div class="Section" data-sectionCode="">
<a name="section-7.4"></a><p></p>
<h2> Use in Hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span>:</h2>
<p class="First"> The elimination half-life of morphine may be prolonged in patients with  reduced metabolic rates and with hepatic and/or renal dysfunction.  Hence, care should be exercised in administering Astramorph/PF  epidurally to patients with these conditions, since high blood morphine  levels, due to reduced clearance, may take several days to develop.  </p>
</div>
<div class="Section" data-sectionCode="">
<a name="section-7.5"></a><p></p>
<h2> Use in Biliary Surgery or Disorders of the Biliary Tract:</h2>
<p class="First"> As significant morphine is released into the systemic circulation from  neuraxial administration, the ensuing smooth muscle <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonicity</span> may  result in <span class="product-label-link" type="condition" conceptid="4291807" conceptname="Biliary colic">biliary colic</span>. </p>
</div>
<div class="Section" data-sectionCode="">
<a name="section-7.6"></a><p></p>
<h2> Use with Disorders of the Urinary System:</h2>
<p class="First"> Initiation of neuraxial opiate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is frequently associated with  disturbances of micturition, especially in males with prostatic  enlargement. Early recognition of difficulty in urination and prompt  intervention in cases of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> is indicated. </p>
</div>
<div class="Section" data-sectionCode="">
<a name="section-7.7"></a><p></p>
<h2> Use in Ambulatory Patients:</h2>
<p class="First"> Patients with reduced circulating blood volume, impaired myocardial  function or on sympatholytic drugs should be monitored for the possible  occurrence of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, a frequent complication in  single-dose neuraxial morphine <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. </p>
</div>
<div class="Section" data-sectionCode="">
<a name="section-7.8"></a><p></p>
<h2> Use with Other Central Nervous System Depressants:</h2>
<p class="First"> The depressant effects of morphine are potentiated by the presence of  other CNS depressants such as alcohol, sedatives, antihistaminics or  psychotropic drugs. Use of neuroleptics in conjunction with neuraxial  morphine may increase the risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.9"></a><p></p>
<h2> Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First"> Morphine is without known carcinogenic or mutagenic effects and is not  known to impair fertility at non-narcotic doses in animals, but studies  of the carcinogenic and mutagenic potential or the effect on fertility  of Astramorph/PF have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.10"></a><p></p>
<h2> Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.10.1"></a><p></p>
<h3><span class="Italics">Teratogenic Effects—Pregnancy Category C:</span></h3>
<p class="First"> Morphine sulfate is not teratogenic in rats at 35 mg/kg/day  (thirty-five times the usual human dose) but does result in increased  pup mortality and <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> at doses that narcotize the animal  (&gt;10 mg/kg/day, ten times the usual human dose). Astramorph/PF should  only be given to pregnant women when no other method of controlling  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is available and means are at hand to manage the delivery and  perinatal care of the opiate-dependent infant.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-7.10.2"></a><p></p>
<h3>
<span class="Italics">Nonteratogenic Effects:</span><span class="Italics">:</span>
</h3>
<p class="First"> Infants born to mothers who have been taking morphine chronically may  exhibit withdrawal symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.11"></a><p></p>
<h2> Labor and Delivery:</h2>
<p class="First"><span class="Italics">Intravenous</span>  morphine readily passes into the fetal circulation and may result in  <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the neonate.  Naloxone and resuscitative  equipment should be available for reversal of narcotic-induced  <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the neonate.  In addition, intravenous  morphine may reduce the strength, duration and frequency of uterine  contraction resulting in <span class="product-label-link" type="condition" conceptid="434714" conceptname="Prolonged second stage of labor">prolonged labor</span>.</p>
<p><span class="Italics">Epidurally </span> and <span class="Italics">intrathecally</span>  administered morphine readily passes into the fetal circulation and  may result in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> of the neonate.  Controlled  clinical studies have shown that <span class="Italics">epidural </span> administration has little or no effect on the relief of labor  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.12"></a><p></p>
<h2> Nursing Mothers:</h2>
<p class="First"> Morphine is excreted in maternal milk.  Effect on the nursing infant is  not known.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.13"></a><p></p>
<h2> Pediatric Use:</h2>
<p class="First"> Adequate studies, to establish the safety and effectiveness of spinal  morphine in pediatric patients, have not been performed, and usage in  this population is not recommended. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.14"></a><p></p>
<h2> Geriatric Use:</h2>
<p class="First"> The pharmacodynamic effects of neuraxial morphine in the elderly are  more variable than in the younger population. Patients will vary widely  in the effective initial dose, rate of development of tolerance and the  frequency and magnitude of associated adverse effects as the dose is  increased. Initial doses should be based on careful clinical  observation following "test doses", after making due allowances for the  effects of the patient's age and infirmity on his/her ability to clear  the drug, particularly in patients receiving epidural morphine.  </p>
<p> Elderly patients may be more susceptible to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>  and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> following administration of  morphine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="robinsonja1130788222422"></a><a name="section-8"></a><p></p>
<h1> ADVERSE REACTIONS:</h1>
<p class="First"> The most serious adverse experience encountered during administration  of Astramorph/PF is <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.  This <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> may be severe and could  require intervention. (See <a href="#robinsonja1130788196016"> WARNINGS</a>  and <a href="#robinsonja1130788274280"> OVERDOSAGE</a> ) Because of delay in maximum CNS effect with intravenously  administered drug (30 min), rapid administration may result in  overdosing. Single-dose neuraxial administration may result in acute or  delayed <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> for periods at least as long as 24  hours. </p>
<div class="Section" data-sectionCode="">
<a name="section-8.1"></a><p></p>
<h2> Tolerance and <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">Myoclonus</span>:</h2>
<p class="First"> See<span class="Bold"><a href="#robinsonja1130788196016">  WARNINGS </a></span> for discussion of these and related hazards. </p>
<p> While low doses of intravenously administered morphine have little  effect on cardiovascular stability, high doses are excitatory,  resulting from <span class="Bold">sympathetic <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span></span>  and increase in circulating catecholamines. Excitation of the central  nervous system, resulting in <span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span></span> , may accompany high doses of morphine given intravenously. <span class="Bold">Dysphoric reactions</span>  may occur after any size dose and <span class="Bold">toxic psychoses</span>  have been reported. </p>
</div>
<div class="Section" data-sectionCode="">
<a name="section-8.2"></a><p></p>
<h2> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>:</h2>
<p class="First"> Single-dose epidural or intrathecal administration is accompanied by a  high incidence of <span class="Bold"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></span>  that is dose-related but not confined to the site of administration.  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, following continuous infusion of epidural or intrathecal  morphine, is occasionally reported in the literature; these reactions  are poorly understood as to their cause. </p>
</div>
<div class="Section" data-sectionCode="">
<a name="section-8.3"></a><p></p>
<h2> <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span>:</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>, which may persist 10 to 20 hours following single  epidural or intrathecal administration, is a frequent side effect and  must be anticipated primarily in male patients, with a somewhat lower  incidence in females. Also frequently reported in the literature is the  occurrence of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> during the first several days of  hospitalization for the initiation of continuous intrathecal or  epidural morphine therapy. Patients who develop <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> have  responded to cholinomimetic treatment and/or judicious use of catheters  (see <a href="#robinsonja1130788473512"> PRECAUTIONS</a> ). </p>
</div>
<div class="Section" data-sectionCode="">
<a name="section-8.4"></a><p></p>
<h2> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>:</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> is frequently encountered during continuous infusion of  morphine; this can usually be managed by conventional therapy.  </p>
</div>
<div class="Section" data-sectionCode="">
<a name="section-8.5"></a><p></p>
<h2> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>:</h2>
<p class="First"> Lumbar puncture-type <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> is encountered in a significant minority  of cases for several days following intrathecal catheter implantation;  this, generally, responds to bed rest and/or other conventional  therapy.<span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="">
<a name="section-8.6"></a><p></p>
<h2> Other:</h2>
<p class="First"> Other adverse experiences reported following morphine therapy include--  <span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, reduced male potency, decreased libido in men and women, and menstrual irregularities including <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex, interference  with thermal regulation and <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span></span> . Evidence of histamine release such as <span class="Bold"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></span> , <span class="Bold"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span></span>  and/or <span class="Bold">local tissue irritation</span>  may occur. <span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span>  and <span class="Bold"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></span> are frequently seen in patients following morphine  administration. </p>
<p> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, if associated with  continuous infusion therapy, may respond to intravenous administration  of a low dose of naloxone (0.2 mg). The risks of using narcotic  antagonists in patients chronically receiving narcotic therapy should  be considered.</p>
<p> In general, side effects are amenable to reversal by narcotic  antagonists. </p>
<p><span class="Bold">NALOXONE INJECTION AND RESUSCITATIVE EQUIPMENT SHOULD BE IMMEDIATELY  AVAILABLE FOR ADMINISTRATION IN CASE OF LIFE-THREATENING OR INTOLERABLE  SIDE EFFECTS AND WHENEVER ASTRAMORPH/PF THERAPY IS BEING  INITIATED.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="robinsonja1130788114267"></a><a name="section-9"></a><p></p>
<h1> DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="section-9.1"></a><p></p>
<h2> Controlled Substance:</h2>
<p class="First"> Morphine sulfate is a Schedule II narcotic under the United States  Controlled Substance Act (21 U.S.C. 801-886).</p>
<p> Morphine is the most commonly cited prototype for narcotic substances  that possess an addiction-forming or addiction-sustaining liability. A  patient may be at risk for developing a <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> to morphine if used  improperly or for overly long periods of time. As with all potent  opioids which are µ-agonists, tolerance as well as psychological  and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> to morphine may develop irrespective of the  route of administration (intravenous, intramuscular, intrathecal,  epidural or oral). Individuals with a prior history of opioid or other  <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, being more apt to respond to the  euphorigenic and reinforcing properties of morphine, would be  considered to be at greater risk. </p>
<p> Care must be taken to avert withdrawal in patients who have been  maintained on parenteral/oral narcotics when epidural or intrathecal  administration is considered. Withdrawal symptoms may occur when  morphine is discontinued abruptly or upon administration of a narcotic  antagonist.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="robinsonja1130788274280"></a><a name="section-10"></a><p></p>
<h1> OVERDOSAGE:</h1>
<p class="First"><span class="Bold">PARENTERAL ADMINISTRATION OF NARCOTICS IN PATIENTS RECEIVING EPIDURAL  OR INTRATHECAL MORPHINE MAY RESULT IN OVERDOSAGE. </span></p>
<p> Overdosage of morphine is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, with  or without concomitant <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. In severe overdosage, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>,  <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. Since  <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> may result either through direct <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the  respiratory center or as the result of <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, primary attention  should be given to the establishment of adequate respiratory exchange  through provision of a patent airway and institution of assisted, or  controlled, ventilation. The narcotic antagonist, naloxone, is a  specific antidote. An initial dose of 0.4 to 2 mg of naloxone should be  administered intravenously, simultaneously with respiratory  resuscitation. If the desired degree of counteraction and improvement  in respiratory function is not obtained, naloxone may be repeated at 2-  to 3-minute intervals. If no response is observed after 10 mg of  naloxone has been administered, the diagnosis of narcotic-induced, or  partial narcotic-induced, toxicity should be questioned. Intramuscular  or subcutaneous administration may be used if the intravenous route is  not available. </p>
<p> As the duration of effect of naloxone is considerably shorter than that  of epidural or intrathecal morphine, repeated administration may be  necessary. Patients should be closely observed for evidence of  renarcotization.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1> DOSAGE AND ADMINISTRATION:</h1>
<p class="First"> Astramorph/PF  is intended for intravenous, epidural or intrathecal  administration.</p>
<div class="Section" data-sectionCode="">
<a name="section-11.1"></a><p></p>
<h2> Intravenous Administration:</h2>
<div class="Section" data-sectionCode="">
<a name="section-11.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Dosage:</span></p>
<p> The initial dose of morphine sulfate should be 2 mg to 10 mg/70 kg of  body weight.  No information is available regarding the use of  Astramorph/PF in patients under the age of 18.</p>
<div class="Section" data-sectionCode="">
<a name="section-11.1.1.1"></a><p></p>
<h4> Geriatric Use:</h4>
<p class="First"> Administer with extreme caution (See <a href="#robinsonja1130788473512"> PRECAUTIONS</a> .)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="">
<a name="section-11.2"></a><p></p>
<h2> Epidural Administration:</h2>
<p class="First"> ASTRAMORPH/PF SHOULD BE ADMINISTERED EPIDURALLY BY OR UNDER THE  DIRECTION OF A PHYSICIAN EXPERIENCED IN THE TECHNIQUE OF EPIDURAL  ADMINISTRATION AND WHO IS THOROUGHLY FAMILIAR WITH THE LABELING. IT  SHOULD BE ADMINISTERED ONLY IN SETTINGS WHERE ADEQUATE PATIENT  MONITORING IS POSSIBLE. RESUSCITATIVE EQUIPMENT AND A SPECIFIC  ANTAGONIST (NALOXONE INJECTION) SHOULD BE IMMEDIATELY AVAILABLE FOR THE  MANAGEMENT OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> AS WELL AS COMPLICATIONS WHICH  MIGHT RESULT FROM INADVERTENT INTRATHECAL OR INTRAVASCULAR INJECTION.  (NOTE: INTRATHECAL DOSAGE IS USUALLY 1/10 THAT OF EPIDURAL DOSAGE.)  <span class="Bold">PATIENT MONITORING SHOULD BE CONTINUED FOR AT LEAST 24 HOURS AFTER EACH  DOSE, SINCE DELAYED <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> MAY OCCUR.</span></p>
<p> Proper placement of a needle or catheter in the epidural space should  be verified before Astramorph/PF is injected.  Acceptable techniques  for verifying proper placement include:  a) <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> to check for  absence of blood or cerebrospinal fluid, or b) administration of 5 mL  (3 mL in obstetric patients) of 1.5% PRESERVATIVE-FREE Lidocaine and  Epinephrine (1:200,000) Injection and then observe the patient for lack  of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (this indicates that vascular injection has <span class="Italics">not</span>  been made) and lack of sudden onset of segmental anesthesia (this  indicates that intrathecal injection has not<span class="Italics"></span>   been made).</p>
<div class="Section" data-sectionCode="">
<a name="section-11.2.1"></a><p></p>
<h3> Epidural Adult Dosage:</h3>
<p class="First"> Initial injection of 5 mg in the lumbar region may provide satisfactory  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief for up to 24 hours.  If adequate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief is not  achieved within one hour, careful administration of incremental doses  of 1 to 2 mg at intervals sufficient to assess effectiveness may be  given.  No more than 10 mg/24 hr should be administered.  </p>
<p> Thoracic administration has been shown to dramatically increase the  incidence of early and late <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> even at doses of 1  to 2 mg.</p>
<p> For continuous infusion an initial dose of 2 to 4 mg/24 hours is  recommended.  Further doses of 1 to 2 mg may be given if <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief is  not achieved initially.</p>
<div class="Section" data-sectionCode="">
<a name="section-11.2.1.1"></a><p></p>
<h4> Geriatric Use:</h4>
<p class="First"> Administer with extreme caution. (See <a href="#robinsonja1130788473512"> PRECAUTIONS</a> .)  </p>
</div>
</div>
<div class="Section" data-sectionCode="">
<a name="section-11.2.2"></a><p></p>
<h3> Epidural Pediatric Use:</h3>
<p class="First"> No information on use in pediatric patients is available. (See  <a href="#robinsonja1130788473512"> PRECAUTIONS</a> .)</p>
</div>
</div>
<div class="Section" data-sectionCode="">
<a name="section-11.3"></a><p></p>
<h2> Intrathecal Administration:</h2>
<p class="First"><span class="Bold">NOTE:  INTRATHECAL DOSAGE IS USUALLY 1/10 THAT OF EPIDURAL  DOSAGE</span> .</p>
<p> ASTRAMORPH/PF SHOULD BE ADMINISTERED INTRATHECALLY BY  OR UNDER THE  DIRECTION OF A PHYSICIAN EXPERIENCED IN THE TECHNIQUE OF INTRATHECAL  ADMINISTRATION AND WHO IS THOROUGHLY FAMILIAR WITH THE LABELING.  IT  SHOULD BE ADMINISTERED ONLY IN SETTINGS WHERE ADEQUATE PATIENT  MONITORING IS POSSIBLE.  RESUSCITATIVE EQUIPMENT AND A SPECIFIC  ANTAGONIST (NALOXONE INJECTION) SHOULD BE IMMEDIATELY AVAILABLE FOR THE  MANAGEMENT OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> AS WELL AS COMPLICATIONS WHICH  MIGHT RESULT FROM INADVERTENT INTRAVASCULAR INJECTION.  <span class="Bold">PATIENT MONITORING SHOULD BE CONTINUED FOR AT LEAST 24 HOURS AFTER EACH  DOSE, SINCE DELAYED <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> MAY OCCUR.</span>   <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> (BOTH EARLY AND LATE ONSET) HAS OCCURRED MORE  FREQUENTLY FOLLOWING INTRATHECAL ADMINISTRATION THAN EPIDURAL  ADMINISTRATION.</p>
<div class="Section" data-sectionCode="">
<a name="section-11.3.1"></a><p></p>
<h3><span class="Italics">Intrathecal Adult Dosage:</span></h3>
<p class="First"> A single injection of 0.2 to 1 mg may provide satisfactory <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief  for up to 24 hours.  (CAUTION:  THIS IS ONLY 0.4 TO 2 ML OF THE  5  MG/10ML AMPULE/VIAL OR 0.2 TO 1 ML OF THE 10 MG/10 ML AMPULE/VIAL OF  ASTRAMORPH/PF.)  DO NOT INJECT INTRATHECALLY MORE THAN 2 ML OF THE  5  MG/10 ML AMPULE/VIAL OR 1 ML OF THE 10 MG/10ML AMPULE/VIAL.  USE IN THE  LUMBAR AREA ONLY IS RECOMMENDED.  Repeated intrathecal injections of  Astramorph/PF are not recommended.  A constant intravenous infusion of  naloxone, 0.6 mg/hr, for 24 hours after intrathecal injection may be  used to reduce the incidence of potential side effects.</p>
<div class="Section" data-sectionCode="">
<a name="section-11.3.1.1"></a><p></p>
<h4> Geriatric Use:</h4>
<p class="First"> Administer with extreme caution. (See <a href="#robinsonja1130788473512"> PRECAUTIONS</a> .)  </p>
</div>
</div>
<div class="Section" data-sectionCode="">
<a name="section-11.3.2"></a><p></p>
<h3>
<span class="Italics">Repeat Dosage</span><span class="Italics">:</span>
</h3>
<p class="First"> If <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> recurs, alternative routes of administration should be  considered, since experience with repeated doses of morphine by the  intrathecal route is limited.</p>
<div class="Section" data-sectionCode="">
<a name="section-11.3.2.1"></a><p></p>
<h4> Intrathecal Pediatric Use:</h4>
<p class="First"> No information on use in pediatric patients is available. (See  <a href="#robinsonja1130788473512"> PRECAUTIONS</a> .)</p>
</div>
</div>
</div>
</div>
<div class="Section">
<a name="section-12"></a><p></p>
<h1> SAFETY AND HANDLING INSTRUCTIONS</h1>
<p class="First"> Astramorph/PF is supplied in sealed ampules and vials. Accidental  dermal exposure should be treated by the removal of any contaminated  clothing and rinsing the affected area with water. </p>
<p> Each ampule/vial of Astramorph/PF contains a potent narcotic which has  been associated with abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> among health care  providers.<span class="Bold"> Due to the limited indications for this product, the risk of  overdosage and the risk of its diversion and abuse, it is recommended  that special measures be taken to control this product within the  hospital or clinic. </span><span class="Bold Italics">Astramorph/PF should be subject to rigid accounting, rigorous control  of wastage and restricted access. </span></p>
<p><span class="Bold">Parenteral drug products should be inspected for particulate matter and  discoloration prior to administration, whenever solution and container  permit. DO NOT USE IF COLOR IS DARKER THAN <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">PALE</span> YELLOW, IF IT IS  DISCOLORED IN ANY OTHER WAY OR IF IT CONTAINS A PRECIPITATE.</span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1> HOW SUPPLIED</h1>
<p class="First"> Preservative-Free ASTRAMORPH/PF™ (Morphine Sulfate Injection,  USP) is available in ampules and single dose vials for intravenous,  epidural, or intrathecal administration:</p>
<p><span class="Bold">0.5 mg/mL</span></p>
<p> NDC 0186-1159-032 mL (1 mg) Ampule,</p>
<p> Boxes of 10</p>
<p> NDC 0186-1150-0210 mL (5 mg) Ampule, </p>
<p> Boxes of 5</p>
<p> NDC 0186-1152-1210 mL (5 mg) Single Dose Vial, Boxes of 5 E-Z OFF vial  closures</p>
<p><span class="Bold">1 mg/mL</span></p>
<p> NDC 0186-1160-032 mL (2 mg) Ampule,</p>
<p> Boxes of 10</p>
<p> NDC 0186-1151-0210 mL (10 mg) Ampule, Boxes of 5</p>
<p> NDC 0186-1153-1210 mL (10 mg) Single Dose Vial, Boxes of 5 E-Z OFF  vial closures</p>
<div class="Section" data-sectionCode="">
<a name="section-13.1"></a><p></p>
<h2> Storage:</h2>
<p class="First"><span class="Bold">PROTECT FROM LIGHT. Store in carton at 20°-25°C  (68°-77°F), excursions permitted to 15°-30°C  (59°-86°F) [see USP Controlled Room Temperature] until ready  to use. DO NOT FREEZE.</span>    Astramorph/PF contains no preservative or antioxidant.  DISCARD ANY  UNUSED PORTION.  DO NOT HEAT-STERILIZE.  </p>
<p> All trademarks are the property of the AstraZeneca group</p>
<p> © AstraZeneca 2002, 2005</p>
<p> AstraZeneca LP, Wilmington, DE 19850 </p>
<p></p>
<p>30583–00 </p>
<p>Rev. 08/05</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ASTRAMORPH 		
					</strong><br><span class="contentTableReg">morphine sulfate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0186-1159</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">EPIDURAL, INTRATHECAL, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Morphine Sulfate</strong> (Morphine) </td>
<td class="formItem"></td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>nitrogen</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0186-1159-03</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ASTRAMORPH 		
					</strong><br><span class="contentTableReg">morphine sulfate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0186-1160</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">EPIDURAL, INTRATHECAL, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Morphine sulfate</strong> (Morphine) </td>
<td class="formItem"></td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>nitrogen</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0186-1160-03</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ASTRAMORPH 		
					</strong><br><span class="contentTableReg">morphine sulfate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0186-1152</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">EPIDURAL, INTRATHECAL, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Morphine sulfate</strong> (Morphine) </td>
<td class="formItem"></td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>nitrogen</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0186-1152-12</td>
<td class="formItem">5  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ASTRAMORPH 		
					</strong><br><span class="contentTableReg">morphine sulfate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0186-1150</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">EPIDURAL, INTRATHECAL, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Morphine sulfate</strong> (Morphine) </td>
<td class="formItem"></td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>nitrogen</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0186-1150-02</td>
<td class="formItem">5  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ASTRAMORPH 		
					</strong><br><span class="contentTableReg">morphine sulfate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0186-1151</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">EPIDURAL, INTRATHECAL, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Morphine sulfate</strong> (Morphine) </td>
<td class="formItem"></td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>nitrogen</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0186-1151-02</td>
<td class="formItem">5  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ASTRAMORPH 		
					</strong><br><span class="contentTableReg">morphine sulfate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0186-1153</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">EPIDURAL, INTRATHECAL, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Morphine sulfate</strong> (Morphine) </td>
<td class="formItem"></td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>nitrogen</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0186-1153-12</td>
<td class="formItem">5  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span> AstraZeneca LP</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>22AC9F4B-443E-7DD4-4087-7961CB491195</div>
<div>Set id: CA44184D-4D3B-4FDA-C288-8C32527EA6CA</div>
<div>Version: 4</div>
<div>Effective Time: 20080806</div>
</div>
</div> <div class="DistributorName"> AstraZeneca LP</div></p>
</body></html>
